Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study (2009)
- Authors:
- USP affiliated authors: HEGG, ROBERTO - FM ; MARANHAO, RAUL CAVALCANTE - FCF
- Unidades: FM; FCF
- DOI: 10.1007/s00280-008-0738-2
- Subjects: NANOPARTÍCULAS; EMULSÕES (FORMAS FARMACÊUTICAS); FARMACOCINÉTICA
- Language: Inglês
- Imprenta:
- Source:
- Título: Cancer Chemotherapy and Pharmacology
- ISSN: 0344-5704
- Volume/Número/Paginação/Ano: v. 63, n. 2, p. 281-287, 2009
- Status:
- Artigo possui versão em acesso aberto em repositório (Green Open Access)
- Versão do Documento:
- Versão submetida (Pré-print)
- Acessar versão aberta:
-
ABNT
PIRES, Luís Antonio et al. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemotherapy and Pharmacology, v. 63, n. 2, p. 281-287, 2009Tradução . . Disponível em: https://doi.org/10.1007/s00280-008-0738-2. Acesso em: 01 abr. 2026. -
APA
Pires, L. A., Hegg, R., Valduga, C. J., Graziani, S. R., Rodrigues, D. G., & Maranhão, R. C. (2009). Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemotherapy and Pharmacology, 63( 2), 281-287. doi:10.1007/s00280-008-0738-2 -
NLM
Pires LA, Hegg R, Valduga CJ, Graziani SR, Rodrigues DG, Maranhão RC. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study [Internet]. Cancer Chemotherapy and Pharmacology. 2009 ; 63( 2): 281-287.[citado 2026 abr. 01 ] Available from: https://doi.org/10.1007/s00280-008-0738-2 -
Vancouver
Pires LA, Hegg R, Valduga CJ, Graziani SR, Rodrigues DG, Maranhão RC. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study [Internet]. Cancer Chemotherapy and Pharmacology. 2009 ; 63( 2): 281-287.[citado 2026 abr. 01 ] Available from: https://doi.org/10.1007/s00280-008-0738-2 - Avaliação de captação de uma emulsão lipídica semelhante a LDL em carcinoma de mama
- One hour infusion of clodronate disodium for treating oncological pain due to bone metastases of solid tumors among adults
- Transfer of lipids to HDL in patients with breast cancer
- One hour infusion of clodronate disodium for treating oncological pain due to bone metastases of solid tumors among adults
- Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide
- Use of cholesterol-rich microemulsion that binds to low-density lipotein (LDL) receptors as avehicle for etoposide
- Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemotherapy
- Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemothrapy
- Uptake of a cholesterol-rich emulsion by breast cancer
- Effect of neoadjuvant chemotherapy on low-density lipoprotein (LDL) receptor and LDL receptor-related protein 1 (LRP-1) receptor in locally advanced breast cancer
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
